RATIONALE-315
Regimen
- Experimental
- neoadj tislelizumab+chemo → adjuvant tislelizumab
- Control
- neoadj chemo → placebo
Population
Chinese resectable stage II-IIIA NSCLC
Key finding
MPR 56.2% vs 15.0%; EFS HR 0.56 (0.40-0.79); tislelizumab perioperative
Source: PMID 39581197
Timeline
- Enrollment start: 2020-05-29 📎
Guideline citations
- CSCO NSCLC 2025 ⚠️ OCR source